{
  "docId": "019de074-2557-77dc-997c-34813158de99",
  "docSlug": "5df8d2698ec92d4699700c9c99264cb6",
  "documentTitle": "Alkermes | Investor Presentation Deck | 28 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 28,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "before_after",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide presents preclinical efficacy data for RDC-264177 using a DTA mouse model.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-2557-77dc-997c-34813158de99/16",
  "deckHref": "/decks/019de074-2557-77dc-997c-34813158de99",
  "deckJsonHref": "/decks/019de074-2557-77dc-997c-34813158de99.json",
  "deckAnchorHref": "/decks/019de074-2557-77dc-997c-34813158de99#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.1,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Wakefulness",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d21d78a-7370-471f-8552-7c48483a3bd5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.55,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Cataplexy",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82db620a-337a-4b0f-91c6-4eb6b6fc479d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.1,
        "y": 0.78
      },
      "kind": "paragraph",
      "text": "DTA mouse model of narcolepsy1,2 believed to serve as a predictive disease model of narcolepsy in humans",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1bd583d0-a5c6-49e4-8be9-d2719bb9e3bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "Tabuchi S, Tsunematsu T, Black SW, et al. Conditional ablation of orexin/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function. J Neurosci. 2014;34(19):6495-6509. In collaboration with SRI International",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3be7d3c7-946a-46e9-bec4-5a318034f267",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Selective OX2R Agonist Showed Dose-Dependent Increased Wakefulness and Reduced Cataplexy in Preclinical Models",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "684ddab2-3a45-42be-adc8-85c684907180",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "77502f05-75e3-4e3b-b850-16c22c5edfc5",
      "evidence": "Selective OX2R Agonist Showed Dose-Dependent Increased Wakefulness and Reduced Cataplexy in Preclinical Models with before/after charts",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 13,
      "beatId": "455311ba-8ac4-47bd-a45a-0bcdde58b22a",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The deck outlines clear priorities and a roadmap for growth.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 19,
      "from": 13,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "720f4a4f-461e-4591-8c2c-8988df913da8",
      "evidence": "The deck presents the clinical development plan and timeline.",
      "position": 1,
      "objective": "Why is now the right time to advance the orexin 2 receptor agonist?",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.6,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}